2025 China Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 China Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in amyotrophic lateral sclerosis (ALS) treatment in China are Biogen, Mitsubishi Tanabe Pharma Corporation, Sanofi, and Zhimeng Biopharma. Biogen recently launched Tofersen in China (2025), a gene-targeted therapy for SOD1-ALS, marking a significant milestone in precision ALS treatment in the country. Mitsubishi Tanabe Pharma introduced Edaravone (RADICAVA) in China in 2019, which is widely used alongside riluzole, benefitting from increased insurance coverage and awareness among Chinese patients. Sanofi is dedicated to advancing ALS therapies globally and maintains a strong presence in China through innovation and partnerships. Zhimeng Biopharma received approval to initiate phase 2/3 clinical trials for its oral treatment CB03-154 in China, aiming to slow disease progression by modulating nerve cell activity.
These companies contribute significantly to the evolving ALS treatment landscape in China, leveraging innovative therapies like gene therapy, antisense oligonucleotides, and neuroprotective agents. Their efforts align with China’s strategic emphasis on rare diseases and precision medicine, underscored by regulatory support and growing clinical trial activity. The market is expanding due to increased ALS prevalence, enhanced diagnosis, insurance reforms, and international collaborations, positioning these leading companies at the forefront of efforts to address unmet needs in the Chinese ALS patient population.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in amyotrophic lateral sclerosis (ALS) treatment in China are Biogen, Mitsubishi Tanabe Pharma Corporation, Sanofi, and Zhimeng Biopharma. Biogen recently launched Tofersen in China (2025), a gene-targeted therapy for SOD1-ALS, marking a significant milestone in precision ALS treatment in the country. Mitsubishi Tanabe Pharma introduced Edaravone (RADICAVA) in China in 2019, which is widely used alongside riluzole, benefitting from increased insurance coverage and awareness among Chinese patients. Sanofi is dedicated to advancing ALS therapies globally and maintains a strong presence in China through innovation and partnerships. Zhimeng Biopharma received approval to initiate phase 2/3 clinical trials for its oral treatment CB03-154 in China, aiming to slow disease progression by modulating nerve cell activity.
These companies contribute significantly to the evolving ALS treatment landscape in China, leveraging innovative therapies like gene therapy, antisense oligonucleotides, and neuroprotective agents. Their efforts align with China’s strategic emphasis on rare diseases and precision medicine, underscored by regulatory support and growing clinical trial activity. The market is expanding due to increased ALS prevalence, enhanced diagnosis, insurance reforms, and international collaborations, positioning these leading companies at the forefront of efforts to address unmet needs in the Chinese ALS patient population.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
